Priti Patel - 30 Apr 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NGNE)

Role: Chief Medical Officer
Signature: /s/ Sean Smith, as Attorney-in-Fact for Priti Patel
Issuer symbol: NGNE
Transactions as of: 30 Apr 2022
Net transactions value: -$6,749
Form type: 4
Filing time: 03 May 2022, 19:16:40 UTC
Previous filing: 02 Feb 2022
Next filing: 04 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NLTX	Common Stock	Options Exercise	$0	+10,000	+500%	$0.000000	12,000	30 Apr 2022	Direct	F1
transaction	NLTX	Common Stock	Sale	$6,749	-5,538	-46%	$1.22	6,462	02 May 2022	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NLTX	Restricted Stock Units	Options Exercise	$0	+10,000		$0.000000	10,000	30 Apr 2022	Common Stock	10,000	$0.000000	Direct	F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 2,000 shares of common stock acquired by the Reporting Person on November 15, 2021 pursuant to the Issuer's employee stock purchase plan.
F2	The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	Represents the weighted average sale price. The lowest price at which shares were sold was $1.21 and the highest price at which shares were sold was $1.25. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein.
F4	Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F5	The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F6	The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.